Webbplats analys pharmaphorum.com
pharmaphorum | News & views on pharma and biotech’s evolving future
Genereras på Mars 06 2026 13:56 PM
Gammal statistik? UPDATERA !
Ställningen är 56/100
SEO Innehåll
Titel
pharmaphorum | News & views on pharma and biotech’s evolving future
Längd : 67
Perfekt, din titel innehåller mellan 10 och 70 tecken.
Beskrivning
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
Längd : 158
Bra, din metabeskrivning innehåller mellan 70 och 160 tecken.
Nyckelord
Mycket dåligt. Vi har inte lyckats hitta några meta-taggar på din sida. Använd denna meta-tag generator, gratis för att skapa nyckelord.
Og Meta Egenskaper
Bra, din sida drar nytta utav Og.
| Egendom | Innehåll |
|---|---|
| site_name | pharmaphorum |
| url | https://pharmaphorum.com/homepage |
| title | pharmaphorum| News & views on pharma and biotech’s evolving future |
| description | Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future. |
Rubriker
| H1 | H2 | H3 | H4 | H5 | H6 |
| 0 | 7 | 37 | 0 | 12 | 0 |
- [H2] Featured Content
- [H2] Latest News
- [H2] Views & Analysis
- [H2] Deep Dive
- [H2] White Papers & Webinar
- [H2] Podcasts & Video
- [H2] Partner Content
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] The GLP-1 Reckoning
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] What US healthcare companies and medical researchers need to...
- [H3] What US healthcare companies and medical researchers need to...
- [H3] The GLP-1 Reckoning
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] New hope for ovarian cancer, with Alexander Schneider
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] Editor's Picks
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] Lilly unveils employer scheme for weight-loss drug Zepbound
- [H3] What US healthcare companies and medical researchers need to...
- [H3] JPM 2026: What it revealed about biotech’s new reality
- [H3] Pharma’s search loophole is a preview of what comes next
- [H3] Legacy data into living scientific memory
- [H3] The GLP-1 Reckoning
- [H3] GLP-1s: Five years that changed metabolic medicine
- [H3] Redesigning obesity trials for a chronic disease era
- [H3] The trust gap: GLP-1s and the new information economy of obe...
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] The strategic imperative of Integrated Evidence Generation P...
- [H3] Data managers and CRAs warn of rising data quality risks due...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] Collaboration & personalisation in rare disease R&D, with AO...
- [H3] Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...
- [H3] On JPM2026 and healthcare investment today, with Jonah Comst...
- [H3] 7th Dermatology Drug Development Summit Europe
- [H3] The PM Society Launches Pharmony to Support More Effective P...
- [H3] EVERSANA Names Monica Avram Executive Vice President and Chi...
- [H3] Emerging Trends in Personalised Medicine at PHARMAP 2026
- [H3] Book your tickets and join the PM Society for the 40th PM Aw...
- [H5] header links
- [H5] Pharmaphorum menu first category
- [H5] SECTION
- [H5] Channels
- [H5] Channels
- [H5] SUB NAVIGATION
- [H5] US lawmakers take FDA to task over rare diseases record
- [H5] Gilead buys cell therapy partner Arcellx for up to $7.8bn
- [H5] What next for pharma as SCOTUS strikes down Trump tariffs?
- [H5] Novo Nordisk to cut GLP-1 prices in tough US market
- [H5] UK spurs prescribing of obesity jab Mounjaro with GP bonus
- [H5] Pharmaphorum Menu
Bilder
Vi hittade 42 bilder på denna webbsida.
Bra, de flesta eller alla dina bilder innehåller alt-attribut
Text/HTML Ratio
Ratio : 18%
Bra, den här sidans förhållande mellan text till HTML-kod är högre än 15, men lägre än 25 procent.
Flash
Perfekt, inga Flash-innehåll har upptäckts på denna sida.
Iframe
Synd, du har Iframes på webbsidorna vilket innebär att innehållet i en Iframe inte kan indexeras.
SEO Länkar
URL Rewrite
Bra. Dina adressfält ser bra ut!
Understreck i URLen
Vi har upptäckt understreck i din webbadress. Du bör hellre använda bindestreck för att optimera din SEO.
In-page länkar
Vi hittade totalt 136 länkar inklusive 1 länk(ar) till filer
| Anchor | Typ | Juice |
|---|---|---|
| Skip to main content | Interna | Passing Juice |
| BlueSky | Externa | Passing Juice |
| Externa | Passing Juice | |
| youtube | Externa | Passing Juice |
| Get Newsletters | Interna | Passing Juice |
| Media Kit | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Equity and Sustainability | Interna | Passing Juice |
| Research & Development | Interna | Passing Juice |
| Market Access | Interna | Passing Juice |
| Oncology | Interna | Passing Juice |
| Artificial Intelligence | Interna | Passing Juice |
| Patients & Partnerships | Interna | Passing Juice |
| GLP-1 | Interna | Passing Juice |
| Previous Editions | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Videos | Interna | Passing Juice |
| Spotlight on | Interna | Passing Juice |
| ASCO 2025 | Interna | Passing Juice |
| BIO 2025 | Interna | Passing Juice |
| C-Suite Innovators | Interna | Passing Juice |
| ESMO 2025 | Interna | Passing Juice |
| Frontiers Health 2025 | Interna | Passing Juice |
| JP Morgan | Interna | Passing Juice |
| Global Policy Insights | Interna | Passing Juice |
| Events | Interna | Passing Juice |
| close | Externa | Passing Juice |
| Market Access | Interna | Passing Juice |
| Oncology | Interna | Passing Juice |
| Patients & Partnerships | Interna | Passing Juice |
| Commercialisation | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Sales & Marketing | Interna | Passing Juice |
| R&D | Interna | Passing Juice |
| Digital | Interna | Passing Juice |
| Market Access | Interna | Passing Juice |
| Oncology | Interna | Passing Juice |
| Patients | Interna | Passing Juice |
| Live Coverage | Interna | Passing Juice |
| Partner Content | Interna | Passing Juice |
| About us | Interna | Passing Juice |
| Contribute | Interna | Passing Juice |
| Contact us | Interna | Passing Juice |
| Sign in | Interna | Passing Juice |
| China's clears Pfizer GLP-1 ecnoglutide for weight loss | Interna | Passing Juice |
| J&J's Tecvayli claims third national priority FDA approval | Interna | Passing Juice |
| The GLP-1 Reckoning | Interna | Passing Juice |
| Alnylam bets on Tenaya RNAi tech, and other licensing news | Interna | Passing Juice |
| What US healthcare companies and medical researchers need to... | Interna | Passing Juice |
| Using AI-driven synthetic personas to take your insights fur... | Interna | Passing Juice |
| AI in clinical development & ‘white space’, with Andrew Mack... | Interna | Passing Juice |
| New hope for ovarian cancer, with Alexander Schneider | Interna | Passing Juice |
| Expert Directed Applied Intelligence: Redefining AI in Life ... | Interna | Passing Juice |
| US lawmakers take FDA to task over rare diseases record | Interna | Passing Juice |
| Gilead buys cell therapy partner Arcellx for up to $7.8bn | Interna | Passing Juice |
| What next for pharma as SCOTUS strikes down Trump tariffs? | Interna | Passing Juice |
| Novo Nordisk to cut GLP-1 prices in tough US market | Interna | Passing Juice |
| UK spurs prescribing of obesity jab Mounjaro with GP bonus | Interna | Passing Juice |
| Subscribe | Interna | Passing Juice |
| Lilly unveils employer scheme for weight-loss drug Zepbound | Interna | Passing Juice |
| JPM 2026: What it revealed about biotech’s new reality | Interna | Passing Juice |
| Pharma’s search loophole is a preview of what comes next | Interna | Passing Juice |
| Legacy data into living scientific memory | Interna | Passing Juice |
| GLP-1s: Five years that changed metabolic medicine | Interna | Passing Juice |
| Redesigning obesity trials for a chronic disease era | Interna | Passing Juice |
| The trust gap: GLP-1s and the new information economy of obe... | Interna | Passing Juice |
| The strategic imperative of Integrated Evidence Generation P... | Interna | Passing Juice |
| Data managers and CRAs warn of rising data quality risks due... | Interna | Passing Juice |
| Collaboration & personalisation in rare disease R&D, with AO... | Interna | Passing Juice |
| Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... | Interna | Passing Juice |
| On JPM2026 and healthcare investment today, with Jonah Comst... | Interna | Passing Juice |
| 7th Dermatology Drug Development Summit Europe | Interna | Passing Juice |
| The PM Society Launches Pharmony to Support More Effective P... | Interna | Passing Juice |
| EVERSANA Names Monica Avram Executive Vice President and Chi... | Interna | Passing Juice |
| Emerging Trends in Personalised Medicine at PHARMAP 2026 | Interna | Passing Juice |
| Book your tickets and join the PM Society for the 40th PM Aw... | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| News | Interna | Passing Juice |
| Views & Analysis | Interna | Passing Juice |
| Deep Dive | Interna | Passing Juice |
| Webinars | Interna | Passing Juice |
| Podcasts | Interna | Passing Juice |
| Video | Interna | Passing Juice |
| White Papers | Interna | Passing Juice |
| Event | Interna | Passing Juice |
| Axtria Ignite 2025 | Interna | Passing Juice |
| Frontiers Health 2024 | Interna | Passing Juice |
| Life Science Industry Report | Interna | Passing Juice |
| World Without Disease Summit | Interna | Passing Juice |
| Pharmaphorum | Interna | Passing Juice |
| Cookie Policy | Interna | Passing Juice |
| Privacy Policy | Interna | Passing Juice |
| Terms & Conditions | Interna | Passing Juice |
| Work for us | Interna | Passing Juice |
SEO Nyckelord
Nyckelord Moln
digital healthcare dive content event white sponsored glp-1 news pharmaphorum
Nyckelord Konsistens
| Nyckelord | Innehåll | Titel | Nyckelord | Beskrivning | Rubriker |
|---|---|---|---|---|---|
| news | 17 |  |
 |
|
|
| white | 11 | |
|
|
|
| event | 10 | |
|
|
|
| healthcare | 9 | |
|
|
|
| content | 9 | |
|
|
|
Användbarhet
Url
Domän : pharmaphorum.com
Längd : 16
Favikon
Bra, din webbplats har en favicon.
Utskriftbart
Vi kunde inte hitta CSS för utskrifter.
Språk
Bra. Ditt angivna språk är en.
Dublin Core
Denna sida drar inte nytta utav Dublin Core.
Dokument
Doctype
HTML 5
Encoding
Perfekt. Din deklarerade teckenuppsättning är UTF-8.
W3C Validity
Errors : 0
Varningar : 0
E-post Sekretess
Bra! Ingen e-postadress har hittats i klartext.
Föråldrad HTML
Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.
Hastighets Tips
|
Utmärkt, din webbplats använder inga nästlade tabeller. |
|
Synd, din webbplats använder sig utav inline stilar. |
|
Bra, din webbplats har få CSS-filer. |
|
Synd, din webbplats har för många JS filer (fler än 6 stycken). |
|
Perfekt, din webbplats utnyttjar gzip. |
Mobil
Mobiloptimering
|
Apple Ikon |
|
Meta Viewport Tagg |
|
Flash innehåll |
Optimering
XML Sitemap
Bra, din webbplats har en XML sitemap.
| https://pharmaphorum.com/sitemap.xml |
Robots.txt
https://pharmaphorum.com/robots.txt
Bra, din webbplats har en robots.txt fil.
Analytics
Bra, din webbplats har ett analysverktyg.
Google Analytics |
PageSpeed Insights
Enhet
Kategorier
Free SEO Testing Tool
Free SEO Testing Tool är en fri SEO verktyg som hjälper dig att analysera din webbplats